These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Experimental endocarditis: a review of its relevance to human endocarditis. Carbon C J Antimicrob Chemother; 1993 May; 31 Suppl D():71-85. PubMed ID: 8335526 [TBL] [Abstract][Full Text] [Related]
8. Activity of sulbactam in combination with ceftriaxone in vitro and in experimental endocarditis caused by Escherichia coli producing SHV-2-like beta-lactamase. Fantin B; Pangon B; Potel G; Caron F; Vallée E; Vallois JM; Mohler J; Buré A; Philippon A; Carbon C Antimicrob Agents Chemother; 1990 Apr; 34(4):581-6. PubMed ID: 2188586 [TBL] [Abstract][Full Text] [Related]
9. Integration of pharmacokinetic and pharmacodynamic indices of marbofloxacin in turkeys. Haritova AM; Rusenova NV; Parvanov PR; Lashev LD; Fink-Gremmels J Antimicrob Agents Chemother; 2006 Nov; 50(11):3779-85. PubMed ID: 16940071 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of ampicillin plus ceftriaxone in treatment of experimental endocarditis due to Enterococcus faecalis strains highly resistant to aminoglycosides. Gavaldà J; Torres C; Tenorio C; López P; Zaragoza M; Capdevila JA; Almirante B; Ruiz F; Borrell N; Gomis X; Pigrau C; Baquero F; Pahissa A Antimicrob Agents Chemother; 1999 Mar; 43(3):639-46. PubMed ID: 10049280 [TBL] [Abstract][Full Text] [Related]
11. Correlation of in vitro activity and pharmacokinetic parameters with effect in vivo for antibiotics. Observations from experimental pneumococcus infection. Frimodt-Møller N Dan Med Bull; 1988 Oct; 35(5):422-37. PubMed ID: 3066588 [TBL] [Abstract][Full Text] [Related]
12. Comparison of in vivo intrinsic activity of cefepime and imipenem in a Pseudomonas aeruginosa rabbit endocarditis model: effect of combination with tobramycin simulating human serum pharmacokinetics. Navas D; Caillon J; Gras-Le Guen C; Jacqueline C; Kergueris MF; Bugnon D; Potel G J Antimicrob Chemother; 2004 Oct; 54(4):767-71. PubMed ID: 15317741 [TBL] [Abstract][Full Text] [Related]
13. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Hyatt JM; McKinnon PS; Zimmer GS; Schentag JJ Clin Pharmacokinet; 1995 Feb; 28(2):143-60. PubMed ID: 7736689 [TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamics of Ceftaroline plus Ampicillin against Enterococcus faecalis in an Werth BJ; Shireman LM Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28096164 [TBL] [Abstract][Full Text] [Related]
15. What preclinical data are needed to justify once-daily therapy? Bergeron MG J Clin Pharmacol; 1992 Aug; 32(8):698-705. PubMed ID: 1487558 [TBL] [Abstract][Full Text] [Related]
16. Kinetics and bactericidal effect of gentamicin and latamoxef (moxalactam) in experimental Escherichia coli endocarditis. Contrepois A; Vallois JM; Garaud JJ; Pangon B; Mohler J; Meulemans A; Carbon C J Antimicrob Chemother; 1986 Feb; 17(2):227-37. PubMed ID: 3516963 [TBL] [Abstract][Full Text] [Related]
17. How predictive is PK/PD for antibacterial agents? Frimodt-Møller N Int J Antimicrob Agents; 2002 Apr; 19(4):333-9. PubMed ID: 11978504 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. Rose WE; Rybak MJ; Kaatz GW J Antimicrob Chemother; 2007 Aug; 60(2):334-40. PubMed ID: 17540670 [TBL] [Abstract][Full Text] [Related]
20. In nosocomial pneumonia, optimizing antibiotics other than aminoglycosides is a more important determinant of successful clinical outcome, and a better means of avoiding resistance. Schentag JJ; Birmingham MC; Paladino JA; Carr JR; Hyatt JM; Forrest A; Zimmer GS; Adelman MH; Cumbo TJ Semin Respir Infect; 1997 Dec; 12(4):278-93. PubMed ID: 9436955 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]